Gilead Sciences Inc
Exchange: NASDAQSector: HealthcareIndustry: Drug Manufacturers - General
For more than 35 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention and cure research. Gilead researchers have developed 13 HIV medications, including the first single-tablet regimen to treat HIV, the first antiretroviral for pre-exposure prophylaxis (PrEP) to help reduce new HIV infections, and the first long-acting injectable HIV treatment medication administered twice-yearly. Our advances in medical research have helped to transform HIV into a treatable, preventable, chronic condition for millions of people. Gilead is committed to continued scientific innovation to provide solutions for the evolving needs of people affected by HIV around the world. Through partnerships, collaborations and charitable giving, the company also aims to improve education, expand access and address barriers to care, with the goal of ending the HIV epidemic for everyone, everywhere. Gilead has been recognized as one of the leading philanthropic funders of HIV-related programs in a report released by Funders Concerned About AIDS. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.
Did you know?
Price sits at 65% of its 52-week range.
Current Price
$133.64
+0.56%GoodMoat Value
$120.02
10.2% overvaluedProfile
Valuation (TTM)
Market Cap$165.80B
P/E19.48
EV$187.70B
P/B7.30
Shares Out1.24B
P/Sales5.63
Revenue$29.44B
EV/EBITDA13.48
Gilead Sciences Inc (GILD) Stock Analysis
GoodMoat Analysis
Gilead Sciences is a large, profitable pharmaceutical company with a strong financial profile, but its moat appears limited and the stock is trading above the GoodMoat target price. The analysis suggests proceeding with caution, as the business may not meet the initial quality gate for a deep value investment.
Read full analysis
Gilead Sciences is a major biopharmaceutical company focused on developing and commercializing medicines for life-threatening diseases, primarily in virology and oncology. Applying the GoodMoat framework, the company's competitive advantages are concentrated. It likely scores on criteria like Proprietary Data (from clinical trials), Regulatory Barriers (patents), and Technology Leadership in its core areas, but it faces significant Low Disruption Risk from generic competition as patents expire. A moat score is likely below the 5+ threshold needed to proceed confidently, indicating a lack of durable, wide-moat protection. Financially, Gilead shows high profitability with a 37.5% ROE and a 34.0% operating margin, alongside a solid 5.5% FCF yield. However, revenue growth is modest at 4.7% YoY, and the Debt/Equity ratio of 1.1 indicates a leveraged balance sheet. The current price of $138.26 is above the GoodMoat target of $120.02, suggesting the valuation is not favourable. According to the Decision Framework, the potential moat score below 5 could cause the analysis to fail the initial 'Moat & Quality Gate,' making a deep value case difficult to establish without a more compelling margin of safety. Analysis based on data as of 2024-05-15.
Market Cap$165.80B
Current Price$133.64
P/E Ratio19.48
Forward P/E—
PEG Ratio0.81
EPS$6.78
Book Value$18.30
P/B Ratio7.30
GILD Financial Charts
FCF vs CAPEX
FCFCAPEX
Forward estimates use 2.2% FCF growth (CAGR)
Cash vs Debt
Net Debt: 17.4B
Revenue
22.4B
FY19
24.7B
FY20
27.3B
FY21
27.3B
FY22
27.1B
FY23
28.8B
FY24
29.4B
FY25
Net Income
5.4B
FY19
123M
FY20
6.2B
FY21
4.6B
FY22
5.7B
FY23
480M
FY24
8.5B
FY25
GILD 52-Week Range
$94.39
$154.92
50-Day MA: $142.84200-Day MA: $125.04
Did you know?
Trading 10% above its estimated fair value of $120.02.
Gilead Sciences Inc (GILD) Financial Summary
Gilead Sciences Inc (GILD) is a Healthcare company in the Drug Manufacturers - General industry, listed on NASDAQ. The stock currently trades at $133.64 with a market capitalization of $165.80B.
Key valuation metrics include a P/E ratio of 19.48, price-to-book ratio of 7.30, and EPS of $6.78. The company reports a profit margin of 28.9% and return on equity of 37.5%.
GILD Key Financial Metrics
| Metric | Value |
|---|---|
| Market Cap | $165.80B |
| P/E Ratio | 19.48 |
| EPS | $6.78 |
| P/B Ratio | 7.30 |
| P/S Ratio | 5.63 |
| EV/EBITDA | 13.48 |
| Dividend Yield | 2.41% |
| Profit Margin | 28.9% |
| Return on Equity | 37.5% |
| Debt/Equity | 1.10 |
GILD Revenue & Earnings History
| Year | Revenue | Net Income |
|---|---|---|
| FY19 | $22.45B | $5.39B |
| FY20 | $24.69B | $123.00M |
| FY21 | $27.30B | $6.22B |
| FY22 | $27.28B | $4.59B |
| FY23 | $27.12B | $5.67B |
| FY24 | $28.75B | $480.00M |
| FY25 | $29.44B | $8.51B |
Gilead Sciences Inc (GILD) Valuation
Based on GoodMoat's DCF model, Gilead Sciences Inc has a fair value estimate of $120.02. At the current price of $133.64, the stock appears 11.3% overvalued relative to our intrinsic value estimate.
GILD Quality Indicators
Gilead Sciences Inc maintains a profit margin of 28.9% and an operating margin of 34.0%. Return on equity stands at 37.5%. The current ratio is 1.55. Debt-to-equity ratio is 1.10.
About Gilead Sciences Inc
For more than 35 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention and cure research. Gilead researchers have developed 13 HIV medications, including the first single-tablet regimen to treat HIV, the first antiretroviral for pre-exposure prophylaxis (PrEP) to help reduce new HIV infections, and the first long-acting injectable HIV treatment medication administered twice-yearly. Our advances in medical research have helped to transform HIV into a treatable, preventable, chronic condition for millions of people. Gilead is committed to continued scientific innovation to provide solutions for the evolving needs of people affected by HIV around the world. Through partnerships, collaborations and charitable giving, the company also aims to improve education, expand access and address barriers to care, with the goal of ending the HIV epidemic for everyone, everywhere. Gilead has been recognized as one of the leading philanthropic funders of HIV-related programs in a report released by Funders Concerned About AIDS. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.
GILD Free Cash Flow
Gilead Sciences Inc generated $9.46B in trailing twelve-month free cash flow, representing an FCF yield of 5.70%. This strong FCF yield suggests the company generates substantial cash relative to its market value.
GILD Shares Outstanding
Gilead Sciences Inc has 1.24 billion shares outstanding at a share price of $133.64, giving it a market capitalization of $165.80B.
GILD Recent Insider Trades
Recent insider transactions at Gilead Sciences Inc include:
| Insider | Type | Shares | Value |
|---|---|---|---|
| Dickinson Andrew D (Chief Financial Officer) | SELL | 3,000 | $422880.00 |
| Mercier Johanna (Chief Comm & Corp Aff Officer) | SELL | 3,000 | $422880.00 |
| O'Day Daniel Patrick (Chairman & CEO) | SELL | 10,000 | $1.37M |